Gland Pharma (GLAND) | Stock Overview & Key Data
Gland Pharma Performance Comparison
Stock Range
Today's Range
Low: ₹1,929.70
High: ₹1,972.50
on August 8, 2025
52 Week Range
Low: ₹1,277.80
High: ₹2,131.00
on April 7, 2025
on July 29, 2025
All-Time High: ₹4,350.00 on August 9, 2021
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Market Cap
INR318.7B
EPS
46.79
P/E Ratio (TTM)
41.35
Forward P/E
29.76
P/B Ratio
3.48
PEG Ratio
29.76
Div. Yield
1.15%
ROE
7.63%
Beta
0.400
Debt to Equity
3.43
Financial Highlights
Profitability
Gross Margin
65.39%
Operating Margin
17.71%
Profit Margin
13.47%
Returns and Earnings
Return on Assets (TTM)
6.22%
Return on Equity (TTM)
7.63%
EBITDA
INR15.9B
Net Income (TTM)
INR7.7B
Growth
Revenue (TTM)
Revenue Per Share (TTM)
INR347.20
Quarterly Revenue Growth (YoY)
7.40%
Quarterly Earnings Growth (YoY)
49.90%
Dividend Information
Last 12-Month Dividend
₹20.00
Current Dividend Yield
1.15%
3-Year Average Dividend Yield
1.07%
3-Year Average Annual Dividend
₹6.67
3-Year Total Dividends
₹20.00
Ex-Dividend Date
August 16, 2024
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Gland Pharma GLAND | 318.74B Large-cap | -2.22% | 2.45% | 36.66% | 30.91% | 6.88% | -4.53% | -18.20% | 6.32% |
| Sun Pharmaceutical SUNPHARMA | 3.92T Large-cap | -2.63% | -5.12% | -10.20% | -8.38% | -16.03% | -8.55% | 73.73% | 198.65% |
| Divi's Laboratories DIVISLAB | 1.63T Large-cap | -7.03% | -14.75% | -0.77% | -0.41% | -2.61% | 22.45% | 58.73% | 91.42% |
| Cipla CIPLA | 1.20T Large-cap | -1.18% | -0.22% | -0.12% | 1.79% | 0.38% | 3.58% | 45.16% | 93.18% |
| Torrent TORNTPHARM | 1.22T Large-cap | -2.85% | 7.55% | 12.16% | 11.91% | 4.52% | 7.03% | 132.03% | 25.86% |
| Mankind Pharma MANKIND | 1.05T Large-cap | -3.87% | 1.46% | 1.13% | -1.40% | -14.37% | 15.49% | 76.92% | 76.92% |
Ownership & Short Interest
Insider Ownership
51.84%
Institutional Ownership
34.59%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
425K
Average 90-Day Volume
475K
Gland Pharma Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Gland Pharma would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is GLAND's 52-week high and low?
- In the last 52 weeks, Gland Pharma reached a high of ₹2,131.00 (on July 29, 2025) and a low of ₹1,277.80 (on April 7, 2025).
- What is the market cap and P/E ratio for GLAND?
- Curious about Gland Pharma's size and valuation? Its market capitalization stands at 318.74B. When it comes to valuation, the P/E ratio (trailing twelve months) is 41.35, and the forward P/E (looking ahead) is 29.76.
- Does GLAND pay dividends? If so, what's the yield?
- Yes, Gland Pharma is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 1.15%, and the company has paid an average of ₹6.67 per share annually over the past 3 years.
- Who are Gland Pharma's main competitors or similar companies to consider before investing?
When looking at Gland Pharma, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA3.92T Healthcare Drug Manufacturers - Specialty & Generic -8.55% 73.73% Divi's Laboratories
DIVISLAB1.63T Healthcare Drug Manufacturers - Specialty & Generic 22.45% 58.73% Cipla
CIPLA1.20T Healthcare Drug Manufacturers - Specialty & Generic 3.58% 45.16% Torrent
TORNTPHARM1.22T Healthcare Drug Manufacturers - Specialty & Generic 7.03% 132.03% Mankind Pharma
MANKIND1.05T Healthcare Drug Manufacturers - Specialty & Generic 15.49% 76.92% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Gland Pharma Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Gland Pharma's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 7.63%, the Debt to Equity ratio from the most recent quarter is 3.43, and its Gross Profit Margin stands at 65.39%.
- What is the recent revenue and earnings growth for GLAND?
- Looking at Gland Pharma's growth, its revenue over the trailing twelve months (TTM) was INR57B. Compared to the same quarter last year (YoY), quarterly revenue grew by 7.40%, and quarterly earnings saw a YoY growth of 49.90%.
- How much of GLAND stock is held by insiders and institutions?
- Wondering who owns Gland Pharma stock? Company insiders (like executives and directors) hold about 51.84% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 34.59%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.